Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E

Molecular Psychiatry

Volumn 7, Issue 8, 2002, Pages 886-890

  Laws, S M ^a   Hone, E ^a   Taddei, K ^a   Harper, C ^b   Dean, B ^c   McClean, C ^c   Masters, C ^c   Lautenschlager, N ^a   Gandy, S E ^d   Martins, R N ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

491A T; Alzheimer's disease; ApoE levels; APOE 4; Apolipoprotein E

Indexed keywords

APOLIPOPROTEIN E; BRAIN PROTEIN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; AUTOPSY; DNA POLYMORPHISM; FRONTAL CORTEX; GENE LOCUS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; FRONTAL LOBE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 0036382942     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001097     Document Type: Article

References (26)

1. Mahley RW, Innerarity TL, Rall Jr SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-1294.
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
3. Pitas RE, Boyles JK, Lee SH et al. Astrocytes synthesize apolipoprotein E and metabolise apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987; 917: 148-161.
4. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981; 33: 11-24.
5. Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
6. Martins RN, Clarnette R, Fisher C et al. ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. Neuroreport 1995; 6: 1513-1516.
7. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
8. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 1997; 223: 29-33.
9. Laws SM, Taddei K, Martins G et al. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport 1999; 10: 879-882.
10. Artiga MJ, Bullido MJ, Sastre I et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998; 421: 105-108.
11. Bullido MJ, Artiga MJ, Recuero M et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genet 1998; 18: 69-71.
12. Lambert JC, Bert C, Pasquier F et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neuronal APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Gen 1998; 7: 1511-1516.
13. Lambert JC, Pasquier F, Cottel D et al. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Gen 1998; 7: 533-540.
14. Hixson JE, Vernier DT. Restriction of human apolipoprotein E by gene amplification and cleavage with Hla1. J Lipid Res 1990; 31: 545-548.
15. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337: 1158-1159.
16. Diedrich JF, Minnigan H, Carp RI et al. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 1991; 65: 4759-4768.
17. Wang JC, Kwon JM, Shah P et al. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology 2000; 55: 1644-1649.
18. Yamada T, Kondo A, Takamatsu J, Tateishi J, Goto I. Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. J Neurol Sci 1995; 129: 56-61.
19. Yamagata K, Urakami K, Ikeda K et al. High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12: 57-62.
20. Zarow C, Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. Exp Neurol 1998; 149: 79-86.
21. Pirttila T, Soininen H, Heinonen O et al. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res 1996; 722: 71-77.
22. Bales KR, Verina T, Dodel RC et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17: 263-264.
23. Bales KR, Verina T, Cummins DJ et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999; 96: 15233-15238.
24. Holtzman DM, Bales KR, Tenkova T et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892-2897.
25. Holtzman DM, Fagan AM, Mackey B et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000; 47: 739-747.
26. Lambert JC, Mann D, Goumidi L et al. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet 2001; 357: 608-609.